Press releases

Cash position of €9.3 million, and net loss down 1% to €6.3 million Strategic focus on high value-added applications in the healthcare,...

Four directors of international standing and experts in pharmaceutical industry and antibiotics join the Board of Directors: Bernard Fanget...

DEINOVE (Alternext Paris: ALDEI), a biotech company that discovers, develops and produces high-value compounds from rare bacteria, notably...

Completion of the contribution in kind of DEINOBIOTICS’ shares to DEINOVE which now holds 100% of its subsidiary Consequential DEINOVE’s...

Cash position: +€10.4 M at June 30, 2016 compared to +€12.4 M at December 31, 2015 Stability of interim net loss at -€3.1M Strategic...

ADEME has validated the 2nd key milestone of the DEINOCHEM program. Crossing this milestone was conditional on achieving deliverables...

The goal of this competition is to bring out the talents and future champions of the French economy through eight strategic goals set by...

The Tech 40 label recognizes particularly outstanding listed technology companies. Deinove is one of the 40 companies selected from among...

Cash position sharply improved by the December 2015 capital increase Reduction of net loss to €6.4m, vs. €6.5m in 2014 Growth in operating...

The ROTH conference brings together several thousand U.S. investors focused on small and mid-cap growth companies. Emmanuel PETIOT will...